Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
Children and adults with recurrent or progressive malignant brain tumors have a dismal
prognosis, and outcomes remain very poor. Magrolimab is a first-in-class anticancer
therapeutic agent targeting the Cluster of differentiation 47 (CD47)-signal receptor
protein-alpha (SIRP-alpha) axis. Binding of magrolimab to human CD47 on target malignant
cells blocks the "don't eat me" signal to macrophages and enhances tumor cell phagocytosis.
Pre-clinical studies have shown that treatment with magrolimab leads to prolonged survival in
models of Atypical Teratoid Rhabdoid Tumors (ATRT), diffuse intrinsic pontine glioma (DIPG),
high-grade glioma (adult and pediatric), medulloblastoma, and embryonal tumors formerly
called Primitive Neuro-Ectodermal Tumors (PNET). Safety studies in humans have proven that
magrolimab has an excellent safety profile. Ongoing studies are currently testing magrolimab
in adult myelodysplastic syndromes, acute myeloid leukemia, non-Hodgkin lymphoma, colorectal,
ovarian, and bladder cancers. Herein we propose to test the safety of magrolimab in children
and adults with recurrent or progressive malignant brain tumors.